Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACUTE II: Enoxaparin vs Heparin in AF Cardioversion
NCT00289042Phase 4Completed
- Sponsor
- Cleveland Clinic
- Start
- Dec 1999
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in Atrial fibrillation (AFib) (2 arms), sponsored by Cleveland Clinic. Primary endpoints: Ischemic stroke at 5 weeks, Transient Ischemic Attack at 5 weeks and 5 more. Started Dec 1999; status: completed.
02
Drugs
enoxaparin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00289042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00289042.